REMIMAZOLAM

DGAP-News: PAION RECEIVES UK MHRA APPROVAL OF BYFAVO (REMIMAZOLAM) FOR PROCEDURAL SEDATION

Retrieved on: 
Tuesday, June 29, 2021
Anesthesia, Chemical compounds, Organic compounds, GABAA receptor positive allosteric modulators, Pyridines, Remimazolam, Sedation, MHRA, Intensive care unit, Procedural sedation and analgesia, remimazolam, PAION, REMIMAZOLAM, PAION

Aachen (Germany), 29 June 2021 - The specialty pharma company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved Byfavo(R) (remimazolam besylate) in adults for procedural sedation.

Key Points: 
  • Aachen (Germany), 29 June 2021 - The specialty pharma company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved Byfavo(R) (remimazolam besylate) in adults for procedural sedation.
  • The decision follows the approval of the European Commission in the EU (including European Economic Area (EEA) countries) in March 2021.
  • Dr. Jim Phillips, CEO of PAION AG, commented: "We are excited that the MHRA has approved Byfavo(R).
  • In addition to procedural sedation and general anesthesia, intensive care unit (ICU) sedation is another possible indication for remimazolam.